HIV vaccines based on Env of multiple clades of HIV

Details HIV vaccines based on Env of multiple clades of HIV HIV vaccines based on Env of multiple clades of HIV

2007-06-13

2010-02-23

Chen, Stacy B (Department: 1648)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

C424S208100

Reexamination Certificate

active

07666427

ABSTRACT:
In one embodiment, the invention provides a multiclade HIV plasmid DNA or viral vector vaccine including components from different clades of Env (optionally Env chimeras) and Gag-Pol-(optionally)Nef from a single clade. The vaccine of the invention may further include V1, V2, V3, or V4 deletions or combinations thereof. In another embodiment, the invention provides multiclade HIV envelope immunogens.

REFERENCES:
patent: 2003/0064054 (2003-04-01), Dong
patent: WO 97/27311 (1997-07-01), None
patent: WO 01/47955 (2001-07-01), None
patent: WO 02/32943 (2002-04-01), None
patent: WO 02/072754 (2002-09-01), None
patent: WO 03/076591 (2003-09-01), None
Tramont et al., Progress in the Development of an HIV Vaccine, Expert Opin. Emerging Drugs, 2002, 8(1):37-45.
Boaz (IAVI Report, Dec. 2002/Jan. 2003).
Amara, R.R. et al. 2001 “Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.”Science292:69-74.
Barouch, D.H. et al. 2000 “Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination.”Science290:486-492.
Barouch, D.H. et al. 2002 “Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes.”Nature415:335-339.
Bojak, A. et al. 2002 “Muscle specific versus ubiquitous expression of Gag based HIV-1 DNA vaccines: a comparative analysis.”Vaccine20:1975-1979.
Bonnet, M.C. et al. 2000 “Recombinant viruses as a tool for therapeutic vaccination against human cancers.”Immunol. Lett.74:11-25.
Borrow, P. et al. 1994 “Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection.”J. Virol.68:6103-6110.
Cao, H. et al. 1997 “Cytotoxic T-lymphocyte cross-reactivity among different human immunodeficiency virus type 1 clades: implications for vaccine development.”J. Virol.71:8615-23.
Chakrabarti, B.K. et al. 2002 “Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization.”J. Virol.76:5357-5368.
Chakrabarti, B.K. et al. 2005 “Expanded breadth of virus neutralization after immunization with a multiclade envelope HIV vaccine candidate.”Vaccine23:3434-3445.
Deml, L. et al. 2001 “Multiple effects of codon usage optimization on expression and immunogenicity of DNA candidate vaccines encoding the human immunodeficiency virus type 1 Gag protein.”J. Virol.75:10991-11001.
Dorrell, L. et al. 2001 “Cytotoxic T lymphocytes recognize structurally diverse, clade-specific and cross-reactive peptides in human immunodeficiency virus type-1 gag through HLA-B53.”Eur. J. Immunol.31:1747-1756.
Goepfert, P.A. et al. 2000 “A significant number of human immunodeficiency virus epitope-specific cytotoxic T lymphocytes detected by tetramer binding do not produce gamma interferon.”J. Virol.74:10249-10255.
Huang, Y. et al. 2001 “Human immunodeficiency virus type 1-specific immunity after genetic immunization is enhanced by modification of Gag and Pol expression.”J. Virol.75:4947-4951.
Jin, X. et al. 1999 “Dramatic rise in plasma viremia after CD8+ T cell depletion in simian immunodeficiency virus-infected macaques.”J. Exp. Med.189:991-998.
Keating, S.M. et al. 2002 “Cross-clade T lymphocyte-mediated immunity to HIV type 1: implications for vaccine design and immunodetection assays.”AIDS Res. Hum. Retroviruses18:1067-1079.
Kim, J. et al. 2001 “Protection from immunodeficiency virus challenges in rhesus macaques by multicomponent DNA immunization.”Virology285:204-217.
Kjerrstrom, A. et al. 2001 “Interactions of single and combined human immunodeficiency virus type 1 (HIV-1) DNA vaccines.”Virology284:46-61.
Klein, M.R. et al. 1995 “Kinetics of gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics.”J. Exp. Med.181:1365-1372.
Kong, W.P. et al. 2003 “Immunogenicity of multiple gene and clade human immunodeficiency virus type 1 DNA vaccines.”J. Virol.77:12764-12772.
Koup, R.A. et al. 1994 “Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome.”J. Virol.68:4650-4655.
Letvin, N.L. 2002 “Strategies for an HIV vaccine.”J. Clin. Investig.110:15-20.
Maecker, H.T. et al. 2001 “Use of overlapping peptide mixtures as antigens for cytokine flow cytometry.”J. Immunol. Methods255:27-40.
Mascola, J.R. et al. 2001 “Vaccines for the prevention of HIV-1 disease.”Curr. Opin. Immunol.13:489-495.
McKay, P.F. et al. 2002 “Vaccine protection against functional CTL abnormalities in simian human immunodeficiency virus-infected rhesus monkeys.”J. Immunol.168:332-337.
Migueles, S.A. et al. 2001 “Frequency and function of HIV-specific CD8+ T cells.”Immunol. Lett.79:141-150.
Mortara, L. et al. 1998 “Selection of virus variants and emergence of virus escape mutants after immunization with an epitope vaccine.”J. Virol.72:1403-1410.
Moss, B. 1996 “Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety.”PNAS USA93:11341-11348.
Moss, P.A. H. et al. 1995 “Persistent high frequency of human immunodeficiency virus-specific cytotoxic T cells in peripheral blood of infected donors.”PNAS USA92:5773-5777.
Musey, L. et al. 1997 “Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection.”N. Engl. J. Med.337:1267-1274.
Muthumani, K. et al. 2002 “Issues for improving multiplasmid DNA vaccines for HIV-1.”Vaccine20:1999-2003.
Nabel, G.J. 2001 “Challenges and opportunities for development of an AIDS vaccine.”Nature410:1002-1007.
NIAID Phase III HIV vaccine trial to determine correlates of protection will not proceed. NIAID News, Feb. 25, 2002, retrieved from the World Wide Web at htlp:/lwww2.niaid.nih.gov
ewsroom/releaseslphase3hiv.htm.
Novitsky, V. et al. 2001 “Identification of human immunodeficiency virus type 1 subtype C Gag-, Tat-, Rev-, and Nef-specific ELISpot-based cytotoxic T-lymphocyte responses for AIDS vaccine design.”J. Virol.75:9210-9228.
Ogg, G.S. et al. 1998 “Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA.”Science279:2103-2106.
Ramsay, A.J. et al. 1997 “DNA vaccination against virus infection and enhancement of antiviral immunity following consecutive immunization with DNA and viral vectors.”Immunol. Cell Biol.75:382-388.
Rerks-Ngarm et al. 2006 “HIV/AIDS preventive vaccine ‘prime boost’ phase iii trial: foundations and initial lessons learned from Thailand.”AIDS20:1471-1479.
Rowland-Jones, S.L. et al. 1993 “HIV-specific cytotoxic T-cell activity in an HIV-exposed but uninfected infant.”Lancet341:860-861.
Rowland-Jones, S.L. et al. 1995 “HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women.”Nat. Med.1:59-64.
Rowland-Jones, S.L. et al. 1998 “Cytotoxic T cell response to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi.”J. Clin. Investig.102:1758-1765.
Rubinstein, A. et al. 1999 “Immunologic responses of HIV-1-infected study subjects to immunization with a mixture of peptide protein derivative-V3 loop peptide conjugates.”J. Acquir. Immune Defic. Syndr.22:467-476.
Schmitz, J.E. et al. 1999 “Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes.”Science283:857-860.
Shiver, J.W. et al. 2002 “Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity.”Nature415:331-335.
Srivastava, I.K. et al. 2003 &

Affiliated with

Also associated with

Rating

HIV vaccines based on Env of multiple clades of HIV does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with HIV vaccines based on Env of multiple clades of HIV, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and HIV vaccines based on Env of multiple clades of HIV will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4185093